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Glomerular filtration rate (GFR), renal plasma flow (RPF)
and kidney size are elevated in short-term insulin-dependent
diabetics (IDD), [1—5]. A positive correlation between kidney
size and GFR as well as RPF has been demonstrated [3—5].
Insulin treatment of newly diagnosed IDD patients for 3 months
induces a reduction in kidney size and GFR [6]. Morphometric
studies have demonstrated enlargement of glomeruli and in-
creased glomerular filtration surface area in newly diagnosed
and short-term IDD patients [7, 8]. Furthermore, a close
correlation between glomerular filtration surface area and GFR
has been demonstrated in IDD [81. These observations have led
to the suggestion that increased kidney size and glomerular
filtration surface area are the major, even the sole, determinants
of the elevated GFR in IDD [9]. Studies on the effect of
improved metabolic control on GFR have, however, led to the
suggestion that part of the increase in GFR is due to enhanced
RPF and transglomerular filtration pressure [4, 10].
Kidney size and function were measured before and during
the initial week of insulin treatment in newly diagnosed young
IDD patients to evaluate the validity of the above-mentioned
concepts regarding the elevated GFR in IDD patients (morpho-
logical versus functional origin).
Methods
Subjects. Nine newly diagnosed IDD patients (three females,
six males) participated in the study after informed consent.
Mean age was 31 years (20 to 37 years), mean body surface area
was 1.79 m2 (1.57 to 2.00 m2), and mean body weight (expressed
in per cent of ideal weight) was 91% (83 to 102%). None of the
patients received insulin prior to the admission at the Steno
Memorial Hospital. Investigation was begun within 2 days after
admission. None of the patients suffered from intercurrent
illness and none received drugs with the exception of patient
no. 8 who used low-estrogen oral contraceptive pills. All had a
history of classical diabetic symptoms for several weeks, in-
cluding weight loss (2 to 8 kg). All had ketonuria at admission
but none had acidosis; the mean standard bicarbonate was 23.2
mmoles/liter (20.5 to 25.8 mmoles/liter).
Seventeen normal subjects (14 males and three females) with
a mean age of 28 years (22 to 35 years) and a mean surface area
of 1.89 m2 (1.48 to 2.26 m2) served as controls. The data from
the 14 male control subjects were described previously [4].
GFR and RPF were measured using a constant infusion
technique with 1-1 25-iothalamate and 131 -1-hippuran, respec-
tively [11]. Thyroid uptake of radioactive iodide was blocked
with 100 mg of potassium iodide before the study. Measure-
ments were taken in the morning following an overnight fast.
The patients had 1 liter of tap water in the morning and were
given 0.75 liter/hr during the clearance procedure. Measure-
ments were performed in the supine position; the patients sat or
stood only to void. After 60 mm of constant infusion, six
consecutive clearance periods of 20 mm each were evaluated.
The GFR and RPF are given as mean values from all six
clearance periods and corrected to 1.73 m2 body surface. The
mean intra-individual coefficient of variation for the GFR
measurements was 3.9% (0.8 to 10.3%) and for the RPF
measurements 4.7% (1.6 to 10%). Kidney size was measured by
a nontraumatic ultrasound method described previously [4, 121.
The right kidney only was measured because it was easily
accessible by ultrasound. All measurements were performed
twice, and the values were corrected to 1.73 m2 body surface.
The accuracy and precision of the method have been reported
previously [12].
The difference between the calculated volume and the true
kidney volume in an autopsy study on 16 kidneys was 1 ml,
expressed as the mean value. The fifth and 95th percentiles of
this mean were —21 and 27 ml, respectively. The precision of
the ultrasound method was 5.6% in the present study, ex-
pressed as the coefficient of variation on double determinations.
Measurements of kidney volume in three normal subjects three
times a day on 3 consecutive days showed a mean coefficient of
variation of 2.9% in day to day measurements and of 3.2% in
measurements within the same day.
The plasma glucagon concentration was measured after ex-
traction of the plasma by radioimmunoassay, using antiserum K
5563 [13]; the normal fasting range in nondiabetics using this
antiserum is 70 to 120 pg/mI. Plasma human growth hormone
[14] and plasma insulin [15] were measured by radioimmunoas-
says. Plasma cortisol was measured radioimmunologically (Pre-
mix® Kit, Diagnostic Products Corporation, Los Angeles, Cali-
fornia). Blood pressure, hematocrit, standard bicarbonate, and
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Table 1. Mean blood glucose and 24-h urinary glucose excretion in nine newly diagnosed
insulin-dependent diabetics before and during initial insulin treatment




1 0 1 2 3 4 5 6 7 8
1 15.2 11.9 7.8 10.2 8.0 8.3 8.8 8.2 7.9 7.9
2 12.9 11.3 7.0 5.8 6.1 6.0 7.6 5.7 5.9 7.1
3 15.6 6.2 4.9 5.8 8.3 7.0 7.8 5.8 7.8 5.7
4 18.2 13.4 6.8 5.4 8.8 8.3 9.5 8.8 6.0 6.6
5 17,0 8.7 5.7 7.0 10.2 11.5 12.8 9.6 10.4 7.5
6 19.2 8.6 5.2 5.1 6.5 6.1 6.4 7.0 8.4 6.4
7 13.8 9.3 6.7 5.8 6.3 6.9 6.4 8.0 6.1 5.6
8 15.6 8.9 9.2 8.1 8.7 9.9 10.0 10.8 11.8 7.3
9 16.8 11.5 6.3 9.5 8.8 6.8 8.1 9.2 6.5 8.5
Mean 16.0 10.0 6.6 7.0 8.0 7.9 8.6 8.1 7.9 6.9
SEM 0.7 0.7 0.4 0.6 0.5 0.6 0.7 0.6 0.7 0.3
a The mean is 8 to 11 measurements/24 hr.
The day includes only values obtained after the beginning of insulin treatment at 11:30 A.M.
3-OH-butyrate were determined by conventional laboratory
methods. Blood glucose was measured by a glucose oxidase
method [16] and measurements were performed 5 times/24 hr
before insulin treatment, 11 times/24 hr from day 0—3, and 8
times/24 hr for the rest of the investigation period (Table 1).
Procedure. Kidney volume was determined at 7:30 A.M. and
the clearance procedure was started at 8:30 A.M. All hormonal
and metabolic parameters were recorded after the termination
of the 1-hr equilibration period, that is, at 9:30 A.M. Heart rate
and BP were recorded in clearance periods one and six. At day
0 the patients had not yet received any medical treatment
except diet. Immediately following the renal function measure-
ments on day 0, intensive insulin treatment was started. Pa-
tients numbered 2, 4, 5, 6, and 7 were connected to an artificial
betacell (Biostator®) [17] for intravenous feedback control of
their blood glucose. The constants used for the algorithms [18]
were: KR = 70, KF = 67, QI = 40, B! = 80, RI = 12, Fl 400,
BD = 60, RD = 25, QD = 20, and FD 200. The run mode
used was 3:0.
Patients 1, 3, 8, and 9 received multiple subcutaneous injec-
tions (6 to 10/24 hr) of short-acting insulin (Insulin Leo Neutral,
RI Nordisk) guided by the actual blood glucose values that were
measured 11 times/24 hr. The patients were served a diabetic
diet, but the total caloric intake was unrestricted. Potassium
chloride, 60 mEq/24 hr, was given by mouth during the first 3
days of insulin treatment. The patients were disconnected from
the Biostator at 7 A.M. or received the last subcutaneous
injection of neutral insulin at 5 A.M. on day 3 before the second
measurement of kidney size and function. The patients received
treatment between measurements on days 3 and 8 with a
mixture of short-acting and intermediate acting insulin (Insulin
Retard Leo RI) having 3 to 6 injections/24 hr. The last injection
was given at 5 A.M. on day 8. Mean insulin dose between days 0
and 3 was 50 U/24 hr (16 to 70 U124 hr) and between days 3 and
8 41 U/24 hr (12 to 72 U/24 hr). In patient no. 8 no measure-
ments of kidney function were carried out on day 8 because of
practical problems with the intravenous catheters. Patient no. 9
only participated in measurements taken on days 0 and 8.
Statistics. The Wilcoxon matched-pairs test (two-tailed), the
Mann-Whitney test for unpaired observations (two-tailed), and
the linear regression analysis were used for statistical evalua-
tion. Results are stated as mean SEM.
Results
Twenty-four-hour mean blood glucose values and urinary
glucose excretion before and during the first 8 days of insulin
treatment are shown in Table 1. Values for blood glucose, f3-
OH-butyrate in serum and plasma glucagon obtained during the
clearance experiments on the 3 different days decreased signifi-
cantly (Table 2). At the same time plasma insulin levels
increased significantly while no changes in plasma growth
hormone concentrations were observed (Table 2). Plasma corti-
sol values were within normal range and no significant change
was observed: 367 76, 287 37, and 277 30 nmoles/liter,
respectively. GFR, RPF, and the filtration fraction at day 0
were significantly elevated compared to normal subjects (Table
3), and all decreased significantly during the initial 8 days of
insulin treatment (Table 3, Fig. 1). By contrast no significant
changes in kidney volume were observed (Table 3, Fig. 1). GFR
expressed per milliliter of kidney volume (volume of right
kidney multiplied by 2 in order to estimate total kidney volume)
decreased significantly from 0.57 0.04 mllmin x ml kidney
volume in day 0 to 0.46 0.03 mllmin x ml kidney volume (P <
0.05); the corresponding values for RPF were 2.08 0.10
versus 1.92 0.13 mllmin x ml kidney volume (NS). None of
the values, however, were significantly different from the
values in normal subjects: GFR, 0.50 0.05 ml/min x ml
kidney volume; RPF, 2.30 0.12 mI/mm x ml kidney volume
(Table 4).
A statistically significant correlation between the changes in
GFR and RPF (IGFR, iRPF) was found (r = 0.70, P < 0.05).
Urinary output was identical in the clearance experiments:
14.3 0.9, 15.4 1.1, and 14.0 1.2 mllmin on days 0, 3, and
8, respectively. A decline in hematocrit from days 0 (0.43
0.02) to 3 (0.41 0.01); (P < 0.05) and to day 8 (0.40 0.01)
was found.
Discussion
Our study demonstrated that GFR, RPF, filtration fraction,
and kidney size are elevated before beginning insulin treatment
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Table 1. Continued
Urinary glucose excretion, g124 hr
Dayl Ob 1 2 3 4 5 6 7 8
302 32 5 24 9 24 21 9 18 10
98 58 21 1 5 0 II 5 0 8
140 3 4 8 20 6 2 2 0 3
191 55 0 0 17 0 18 6 5 4
161 49 11 12 28 28 70 11 18 0
149 76 1 0 3 2 4 4 0 2
92 20 3 0 2 4 2 2 0 0
87 2 5 0 13 23 0 17 19 2
130 28 12 6 3 2 6 7 3 6
150 36 7 6 11 10 15 7 7 4
22 8 2 3 3 4 7 2 3 1
Table 2. Blood glucose, serum 3-OH-butyrate, and plasma values for insulin, glucagon, and growth hormone obtained during kidney function
measurements in nine newly diagnosed insulin-dependent diabetics before and during initial insulin treatment
Blood glucose Serum 13-OH." butyrate Plasmab insulin Plasmab glucagon Plasma growth" hormone
mmoies/iiter p.moies/iiter jiU/ml pg/mi mU/liter
Day Day Day Day Day












11.8 7.8 5.8 1958 152 183 <4 12 5 90 60 70 3.8 2.8 6.0
9.3 5.4 5.5 1579 1018 222 8 12 18 90 70 65 <1.1 <1.1 2.5
9.0 7.0 5.3 361 373 138 <4 8 6 90 80 80 1.8 <1.1 <1.1
12.1 10.6 4.1 2388 244 40 <4 <4 19 170 170 100 <1.1 5.8 <1.1
12.4 7.6 8.6 2469 644 75 4 26 25 125 80 70 2.4 12.0 8.5
10.1 5.8 3.3 2434 339 238 7 11 8 120 65 70 1.7 <1.1 28.0
11.9 6.7 3.5 2746 597 287 <4 16 10 90 90 80 7.4 13.0 30.0
10.1 7.4 — 1041 193 — 10 14 — 110 75 — 10.0 37.0 —




11.1 7.3 5.1 1817 445 156 6 13 13 111 86 81 3.8 9.2 10.0
0.5 0.6 0.6 263 103 32 1 2 3 9 12 6 1.0 4.3 4.2
<0.01 NS <0.01 <0.05 0.01 NS 0.01 NS NS NS
Mean of values is derived from the first and the last clearance periods.
b Values obtained during the first clearance period at 9:30 A.M.
in newly diagnosed IDD patients, thus confirming the findings
of Mogensen and Andersen [6]. Kidney size and function are
also elevated in short-term IDD patients in ordinary metabolic
control [3—5].
Near-normal blood glucose levels for 8 days, achieved by the
use of an artificial betacell or by multiple subcutaneous injec-
tions of insulin induced a considerable reduction in GFR, RPF,
and filtration fraction while kidney size remained unchanged.
Previous studies in IDD patients have demonstrated a 20%
reduction in GFR during improved metabolic control for 1 to 2
weeks [2, 10]. It should be stressed that neither the previously
mentioned nor the present study have resulted in a complete
normalization of GFR, presumably partly due to the fact that a
complete normalization of the metabolic status was not ob-
tained. In our study, however, GFR was elevated by 44%
before the insulin treatment and was still 20% above normal
after 8 days of strict metabolic control. These data suggest the
GFR elevation consists of two parts, a rapidly reversible part
and a slowly reversible part of approximately the same
magnitude.
Kidney size remained unchanged in the present study. Mor-
phometric studies on the enlargement of the glomerular filtra-
tion surface area in newly diagnosed IDD patients have failed to
demonstrate any changes after 3 months of insulin treatment
[7], a period in which substantial decline in GFR would be
expected. These findings indicate that the "morphological"
concept for the GFR elevation in IDD [6, 9] cannot explain the
rapidly reversible part of the GFR elevation.
The only way strict metabolic control can influence GFR is
by altering one of the well defined determinants of GFR, or the
factors controlling each of these [19]. These determinants
include RPF, controlled by afferent and efferent arteriolar
resistance, transglomerular pressure (P), controlled by hydro-
static and oncotic pressure, and ultrafiltration coefficient (Kf)
equal to the product of the water permeability of the glomerular
capillary and the surface area available for filtration. We found
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Table 3. Glomerular filtration rate, renal plasma flow, filtration fraction, and kidney volume in nine newly diagnosed insulin-dependent
diabetics before and during initial insulin treatment as compared to healthy subjects
Glomerular filtration rate
mi/mm x 1. 73m2
Renal plasma flow




Patient no. Day 0 3 8 Day 0 3 8 Day 0 3 8 Day 0 3 8
204 157 140 579 560 512 0.35 0.28 0.27 121 184 133
2 148 143 137 646 642 641 0.23 0.22 0.21 150 205 181
3 131 123 115 614 625 591 0.21 0.20 0.19 167 169 187
4 167 166 141 691 794 621 0.24 0.21 0.23 157 144 135
5 151 150 127 589 586 565 0.26 0.26 0.23 123 136 119
6 135 110 108 444 381 350 0.30 0.29 0.31 138 153 135
7 165 142 150 715 644 653 0.23 0.22 0.23 181 193 158
8 144 138 — 447 472 — 0.32 0.29 — 123 lii 114
9 198 — 146 682 — 531 0.29 — 0.27 144 — 128
Mean SEM 160 9 141 6 133 5 601 33 588 44 558 35 0.27 0.02 0.25 0.01 0.24 0.01 145 7 162 11 143 9
P (Day 0 vs. 3 and
3 vs. 8) <0.01 NS NS <0.05 <0.05 NS NS NS
P (Day 0 vs. 8) <0.01 <0.01 <0.05 NS
Normal subjects (14, 3)
Mean SEM Ill 3 508 20 0.22 0.01 112 4
P (Diabetics vs.
controls) <0.01 <0.01 <0.01 <0.05 NS NS <0.01 NS NS <0.01 <0.01 <0.01
100
\\\\\\\\\\\\\\\\\\\\\\
a reversible elevation in RPF, and a correlation between LRPF
and GFR. It should be mentioned that errors in urine collec-
tion can affect RPF and GFR equally and thus induce a
tendency to a false correlation. The fact that the mean of values
from six clearance periods is used will, however, reduce this
tendency. Furthermore, it is well established that a close
relationship exists between RPF and GFR as reviewed by
Brenner and Humes [19]. The decline in hematocrit found
during the initial insulin therapy should theoretically favor an
enhancement of GFR, and thus, it cannot explain the changes in
kidney function observed in the present study. We have no
direct information on zP in man. The previous finding of an
unchanged glomerular filtration surface area [7] and the present
finding of a reduction of the filtration fraction induced by
improved metabolic control, suggest an elevated P in newly
diagnosed untreated IDD patients. Studies of glomerular hemo-
dynamics in poorly controlled insulin-treated streptozotocin-
induced diabetic rats have revealed increased GFR, RPF, and
P and increased or normal Kf [20, 211. These results suggest
that elevated RPF and i.P probably are the major determinants
of the rapidly reversible part of the GFR elevation in poorly
controlled IDD patients.
Poorly controlled IDD patients without ketoacidosis are
metabolically characterized by hyperglycemia, hypoinsulin-
emia, hyperglucagonemia [221, normal plasma concentrations
of cortisol [23], and normal fasting growth hormone concentra-
tions [24]. The present findings are in complete agreement
herewith. Elevation of blood glucose by means of intravenous
glucose infusion induces a raise in GFR and RPF in normal man
and in well controlled IDD patients [25—271. This effect has been
shown not to be secondary to changes in plasma volume or
oncotic pressure [27] and not to be a simple osmotic effect of
glucose [251. On the other hand, Mogensen [281, using an oral
glucose load raising plasma glucose from 7.2 to 16.1 mmoles/
liter in IDD patients, found no changes in GFR or RPF. In that
study [28], however, no attempt was made to improve the
metabolic control prior to the experiment. Among the seven
IDD patients in Mogensen's paper [28] three patients with






















Fig. 1. Glomerular filtration rate, renal plasma flow, and kidney volume
before and during initial insulin treatment in nine newly diagnosed
insulin-dependent diabetics (mean SEM). Hatched area shows values
from 17 normal subjects (mean SEM).
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Table 4. Glomerular filtration rate (GFR) and renal plasma flow (RPF) expressed per milliliter estimated kidney volume
(volume of right kidney multiplied by 2) in nine newly diagnosed insulin-dependent diabetics before and during initial insulin treatment




(N = 17)DayO(N = 9)
Day 3(N = 8)
Day8(N = 8)
GFR, mi/mm x ml kidney volume









a p < 0.05 with the Wilcoxon test.
an increase in GFR following oral glucose while in the three
patients with the highest plasma glucose (> 9 mmoles/liter) a
reduction in GFR was seen. Thus, it seems that an elevation of
blood glucose from normoglycemic levels induces an increase
in GFR both in normal man and in IDD patients.
Intravenous injection and infusion of insulin induces a de-
crease in GFR and RPF, but this effect can be completely
abolished by keeping the blood glucose constant [29—33]. These
findings suggest that it is not the lack of insulin but the
associated hyperglycemia which contributes to the elevated
GFR and RPF in IDD patients. Intravenous glucagon infusion
has been found to enhance GFR and RPF in IDD patients [32].
It is well established that growth hormone concentrations are
elevated on a 24-hr basis in poorly controlled IDD patients,
irrespective of the normal fasting levels [24, 331. Recently, we
have demonstrated that 2/24 hr s.c. injections of human growth
hormone (6 U/24 hr) for 7 days induce a rise the GFR and RPF
in normal man [34]. The above-mentioned findings suggest that
hyperglycemia, hyperglucagonemia, and elevated growth hor-
mone concentrations contribute to the rapidly reversible part of
the GFR elevation typically found in poorly controlled IDD
patients.
The slowly reversible part of the GFR elevation in IDD, that
is, the elevation still present after 1 to 2 weeks of improved
metabolic control, may well reflect the enlarged kidney and the
increased glomerular filtration surface area, both of which are
known to be slowly reversible [6, 7].
Summary. GFR, RPF, and kidney size were measured in nine
young recently diagnosed insulin-dependent diabetics before
(days 0) and 3 and 8 days after the beginning of the initial insulin
treatment and in comparable control subjects. Kidney function
was measured by a constant infusion technique using 1-125-
iothalamate and 13 1-1-hippuran. Kidney size was determined by
means of ultrasound.
Before insulin treatment elevated values for GFR (+44%, P
<0.01), RPF (+ 18%, P < 0.05), and kidney size (+29%, P <
0.01) were found. Near-normal metabolic control was achieved
in all patients using either multiple subcutaneous injections of
insulin or an artificial betacell. GFR decreased from 160 9
SEM to 141 6 ml/min x 1.73 m2 (P < 0.01) and further to 133
5 mlImin x 1.73 m2 (P < 0.01, compared to day 0). Renal
plasma flow was 601 33 and 588 44 ml x 1.73 m2 at days 0
and 3, respectively (NS) and decreased to 558 35 mI/mm X
1.73 m2 at day 0 (P < 0.01). By contrast no statistically
significant changes in kidney volume were observed; the results
on day 0, 3 and 8 were 145 7, 162 11 and 143 9 mlIl.73
m2, respectively. The present study demonstrates that kidney
size and function are elevated at the onset of insulin-dependent
diabetes. Near-normal metabolic control for 8 days induces a
reduction but not a complete normalization in kidney function.
From the present observations it is suggested that the rapidly
reversible part of the elevation in GFR cannot be explained by
concomitant changes in kidney and glomerular size (morpholog-
ical origin) but is probably due to a reduction in renal plasma
flow and to a decreased transglomerular pressure (functional
origin).
Acknowledgments
Part of this paper was presented at the 10th Congress of the
International Diabetes Federation, Vienna, Austria, September, 1979.
The study was supported by grants from the Danish Medical Research
Council and Nordisk Insulin Laboratory, Gentofte, Denmark. The
skillful technical assistance of M. Frandsen, U. M. Smidt, and K.
Winther and the secretarial assistance of A. Jerichow are gratefully
acknowledged.
Reprint requests to J. S. Christiansen, M.D. Steno Memorial Hospi-
tal, 2820 Gentofte, Denmark
References
I. STALDER G, SCHMID R, WOLFF MV: Funktionelle Mikroangio-
pathie der Nieren beim behandelten Diabetes Mellitus im Kinde-
salter. Dtsch Med Wochenschr 85:346—350, 1960
2. MOIENSEN CE: Kidney function and glomerular permeability to
macromolecules in juvenile diabetes. Dan Med Bull 19 (suppl 3): 1—
40. 1972
3. MOGENSEN CE, ANDERSEN MJF: Increased kidney size and
glomerular filtration rate in early juvenile diabetes. Diabetes
22:706—712, 1973
4. CHRISTIANSEN JS, GAMMELGAARD J, FRANDSEN M, PARVING H-
H: Increased kidney size, glomerular filtration rate and renal
plasma flow in short-term insulin-dependent diabetics. Diabetolo-
gia 20:451—456, 1981
5. Puic JG, ANTON FM, GRANDE C, PALLARDO LF, ARNALICH F,
GIL A, VAZQUEZ JJ, GARCIA AM: Relation of kidney size to kidney
function in early juvenile diabetes. Diabetologia 20:363—367, 1981
6. MOGENSEN CE, ANDERSEN MJF: Increased kidney size and
glomerular filtration rate in untreated juvenile diabetics: Normal-
ization by insulin treatment. Diabetologia 11:221—224, 1975
7. KROUSTRUP JG, GUNDERSEN HJG, Ø5TERBY R: Glomerular size
and structure in diabetes mellitus. III. Early enlargement of the
capillary surface. Diabetologia 13:207—210, 1977
8. HIR05E K, TSUCHIDA H, ØSTERBY R, GUNDERSEN HJG: A strong
correlation between glomerular filtration rate and filtration surface
in diabetic kidney hyperfunction. J Lab Invest In press, 1981
9. GUNDERSEN HJG, MOGENSEN CE: The relationship between kid-
ney size and function in short-term diabetic patients (letter).
Diabetologia 21:498—499, 1981
10. PARVING H-H, RuTILI F, GRANATH K, NOER I, DECKERT T,
LYNGSØE J, LASSEN NA: Effect of metabolic regulation on renal
leakeness to Dextran molecules in short-term insulin-dependent
diabetics. Diabetologia 17:157—160, 1979
688 Christiansen et a!
11. MOGENSEN CE: Glomerular filtration rate and renal plasma flow in
short-term and long-term juvenile diabetes mellitus. Scand J C/in
Lab Invest 28:91—100, 1971
12. RASMUSSEN SN, HAASE L, KJELDSEN H, HANCKE S: Determina-
tion of renal volume by ultrasound scanning. JCU 6:160—164, 1978
13. HEDING LG: Radioimmunological determination of pancreatic and
gut glucagon in plasma. Diabetologia 7:10—19, 1971
14. HANSSEN KF: Radioimmunoassay of growth hormone in human
plasma. Acta Endocrinol(Copenh) 71:649—664, 1972
15. HEDING LG: Determination of total serum insulin (IRI) in insulin-
treated diabetic patients. Diabetologia 8:260—266, 1972
16. TRINDER P: Determination of glucose in blood using glucose
oxidase with an alternative oxygen receptor. Ann Clin Biochem
6:24—27, 1969
17. PFEIFFER EF, THUM C, CLEMENS AH: The artificial betacell. A
continuous control of blood sugar by external regulation of insulin
infusion (Glucose controlled insulin infusion system). Norm Metab
Res 487:339—342, 1974
18. CLEMENS AH: Control algorithms for artificial betacell. Norm
Metab Res 8(suppl):35—38, 1979
19. BRENNER B, HUMES HD: Mechanisms of glomerular ultrafiltration.
NEnglJMed 297:148—154, 1977
20. HOSTETTER TH: Renal microcirculation in diabetes mellitus. Acta
Endocrino/(Copenh) 97(suppl 242):22—24, 1981
21, JENSEN PK, CHRISTIANSEN JS, STEVENS K, PARVING H-H: Renal
function in diabetic rats. Acta Endocrinol(Copenh) 97(suppl
242):25, 1981
22. GERICH JE, TSALIKIAN E, LORENZI M, SCHNEIDER V, BOHANON
NV, GUSTAVSON 0, KARAM JH: Normalization of fasting hyperglu-
cagonaemia and excessive glucagon response to intravenous argi-
nine in human diabetes mellitus by prolonged infusion of insulin. J
Clin Endocrino! Metab 41:1178—1180, 1975
23. DREJER J, HENDRIKSEN C, NIELSEN LM, BINDER C, HAGEN C,
KEHLET H: Diurnal variations in plasma prolactin, growth hor-
mone, cortisol and blood glucose in labile diabetes mellitus. C/in
Endocrinol 6:57—64, 1977
24. HANSSEN KF: Immunoreactive growth hormone in plasma and
urine in juvenile diabetics before and during initial insulin treat-
ment. Acta Endocrinol(Copenh) 75:50—63, 1974
25. Fox M, THIER 5, ROSENBERG L, SEGAL 5: Impaired renal tubular
function induced by sugar infusion in man. J Clin Endocrinol
24:1318—1327, 1964
26. BRØCHNER-MORTENSEN J: The glomerular ifitration rate during
moderate hyperglycemia in normal man. Acta Med Scand 194:31—
37, 1973
27. CHRISTIANSEN IS, FRANDSEN M, PARVING H-H: Effect of intrave-
nous glucose infusion on renal function in normal man and in
insulin-dependent diabetics. Diabetologia 21:368—373, 1981
28. MOGENSEN CE: Glomerular filtration rate and renal plasma flow in
normal and diabetic man during elevation of blood sugar levels.
ScandJ C/in Lab Invest 28:177—182, 1971
29. MOGEN5EN CE, CHRISTENSEN NJ, GUNDERSEN HJG: The acute
effect of insulin on renal hemodynamics and protein excretion in
diabetics. Diabetologia 15:153—157, 1978
30. MOGENSEN CE, CHRISTENSEN NJ, GUNDERSEN HJG: The acute
effect of insulin on heart rate, blood pressure, plasma noradrenaline
and urinary albumin excretion, Diabetologia 18:453—457, 1980
31. CHRISTIANSEN JS, FRANDSEN M, PARVING H-H: The effect of
intravenous insulin infusion on kidney function in insulin-depen-
dent diabetes mellitus. Diabetologia 20:199—204, 1981
32. PARVING H-H, CHRISTIANSEN JS, NOER I, TRONIER B, MOGENSEN
CE: The effect of glucagon infusion on kidney function in short-
term insulin-dependent juvenile diabetics. Diabetologia 19:350—
354, 1980
33. HANSEN AP: Serum growth hormone patterns in juvenile diabetics.
Dan Med Bull 19(suppl l):1—3l, 1972
34. CHRIsTIANSEN JS, GAMMELGAARD J, ØRSKOV H, ANDERSEN AR,
TELMER 5, PARVING H-H: Kidney function and size in normal
subjects before and during growth hormone treatment for one
week. EurJ Clin Invest 11:487—490, 1981
